Top

Asia-Pacific Anti-inflammatory Therapeutics Market- Opportunities and Forecasts, 2014 - 2020)

Category : Pharmaceuticals  | Published Date : March-2016 | Pages : 130
enquire Customize Report GET DISCOUNT

The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Moreover, increasing awareness of anti-inflammatory biologics and favorable government initiatives in the Asia-Pacific region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and uncertain patent legislations, i.e., compulsory licensing in India would continue to impede the market growth.

The industry is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis was the dominant segment accounting for 41.3% of the APAC anti-inflammatory therapeutics market in 2014 and holds potential for growth during the forecast period. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis.

On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for around 50% share of the market, and is expected to grow rapidly during the forecast period. Geographically, the market is segmented into six countries namely Japan, China, India, Australia, South Korea, Indonesia and others. Among these countries, Japan holds the largest share in the industry; however, China is expected to exhibit the fastest growth during the forecast period. Major market players have adopted strategies such as collaborations, indication expansions and product launches to expand their market presence. In 2014, Novartis got marketing approval for the drug Cosentyx (secukinumab) in Japan for the treatment of psoriatic arthritis. The company has filed new patents to overcome the issues of patent expiries of their existing drugs and to gain a prominent market share. The key companies profiled in this report are Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc., Novartis AG, F. Hoffmann-La Roche AG, Eli Lily and Company, AstraZeneca PLC and Amgen.

KEY BENEFITS

  • The report provides a quantitative analysis of the current market and estimations during 20142020 that assist in identifying and capitalizing on the prevailing market opportunities
  • Exhaustive analysis of the market by product type helps in understanding the types of therapeutics and their categories that are currently being used to gain prominence in future
  • Competitive intelligence of leading manufacturers and distributors of anti-inflammatory therapeutics helps in understanding the competitive scenario across the geographies
  • Comprehensive analysis of factors that drive and restrict the growth of the industry has been provided
  • SWOT analysis facilitates the study of internal environment of leading companies for strategic decision-making
  • The country-wise analyses of market conditions have been provided in this report

KEY MARKET SEGMENTS

The Asia-Pacific Anti-inflammatory Therapeutics Market is segmented below:

  • BY INDICATION

    • Arthritis
    • Respiratory diseases
    • Multiple sclerosis
    • Psoriasis
    • Inflammatory bowel disease
    • Other inflammatory diseases
  • BY DRUG CLASS

    • Anti-Inflammatory Biologics
    • Non-Steroidal Anti-inflammatory drugs (NSAIDs)
    • Corticosteroids
  • BY GEOGRAPHY

    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Indonesia
    • Other APAC countries

CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies

3.3 Government Regulations
3.4 Reimbursement Scenario
3.5 Porters Five Force Analysis

3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors

3.6 Value chain analysis
3.7 Clinical Trials
3.8 Patent Analysis
3.9 Market Share Analysis, (2014)
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidences of autoimmune and respiratory conditions:
3.10.1.2 New Drugs in Pipeline
3.10.1.3 Increasing adoption rate of anti-inflammatory drugs

3.10.2 Restraints

3.10.2.1 Side Effects of Anti-Inflammatory Drugs
3.10.2.2 Patent expirations

3.10.3 Opportunities

3.10.3.1 Developing biosimilars for the existing drugs
3.10.3.2 Tapping the emerging markets in developing regions

CHAPTER 4 BY INDICATION

4.1 Arthritis

4.1.1 Market size and forecast
4.1.2 Rheumatoid Arthritis
4.1.3 Osteoarthritis
4.1.4 Ankylosing Spondylitis
4.1.5 Psoriatic Arthritis
4.1.6 Gout

4.2 Respiratory Diseases

4.2.1 Market size and forecast
4.2.2 Asthma
4.2.3 Chronic obstructive pulmonary disease (COPD)

4.3 Multiple Sclerosis

4.3.1 Market size and forecast by region

4.4 Psoriasis

4.4.1 Market size and forecast

4.5 Inflammatory Bowel Disease (IBD)

4.5.1 Market size and forecast
4.5.2 Crohns Disease
4.5.3 Ulcerative Colitis

4.6 Other Inflammatory Diseases

4.6.1 Market size and forecast

CHAPTER 5 BY DRUG CLASS

5.1 Anti-inflammatory Biologics

5.1.1 Key Market Trends
5.1.2 Market Growth factors and opportunities
5.1.3 Market size and forecast

5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.2.1 Key Market Trends
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast

5.3 Corticosteroids

5.3.1 Key Market Trends
5.3.2 Market Growth factors and opportunities
5.3.3 Market size and forecast
5.4 Other anti-inflammatory drugs

CHAPTER 6 BY COUNTRY

6.1 Key market trends
6.2 Key growth factors and opportunities

6.2.1 Market size and forecast

6.3 Japan

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 China

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 India

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 Australia

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 South Korea

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

6.8 Indonesia

6.8.1 Key market trends
6.8.2 Key growth factors and opportunities
6.8.3 Market size and forecast

6.9 Rest of Asia Pacific

CHAPTER 7 COMPANY PROFILES

7.1 Pfizer Inc.

7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis & strategic conclusions

7.2 AbbVie Inc.

7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis & strategic conclusions

7.3 Johnson & Johnson

7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic Moves and Developments
7.3.5 SWOT analysis & strategic conclusions

7.4 GlaxoSmithKline plc

7.4.1 Company Overview
7.4.2 Company snapshot
7.4.3 Business performance:
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions

7.5 Merck & Co., Inc.

7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business Performance
7.5.4 Strategic Moves and Developments
7.5.5 SWOT analysis and strategic conclusions

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions

7.7 F. Hoffmann-La Roche AG

7.7.1 Company profile
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions

7.8 Eli Lily and Company

7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic Moves and Developments
7.8.5 SWOT analysis and strategic conclusions

7.9 AstraZeneca PLC.

7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic Moves and Developments
7.9.5 SWOT analysis and strategic conclusions

7.10 Amgen Inc.

7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic Moves and Developments
7.10.5 SWOT analysis and strategic conclusions

List of Figures

FIG. 1 TYPES OF ANTI-INFALMMATORY THERAPEUTICS
FIG. 2 TOP FACTORS IMPACTING ON ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 3 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 4 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICS MARKET (2012-2015)
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN OF ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS, (2014)
FIG. 8 PFIZER FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 9 PFIZER FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 10 PFIZER FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 11 PFIZER SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 12 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 13 HUMIRA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 14 ABBVIE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 15 JOHNSON & JOHNSON PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 16 JOHNSON & JOHNSON SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 17 GLAXOSMITHKLINES FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 18 GLAXOSMITHKLINE FINANCIAL REVENUES BY THERAPY AREA
FIG. 19 GLAXOSMITHKLINE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 20 MERCK FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 21 MERCK FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 MERCK SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 23 NOVARTIS FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 24 NOVARTIS FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 25 NOVARTIS SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 26 ROCHE FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 27 ROCHE FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 28 ROCHE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 29 ELI LILLY FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 30 ELI LILLY SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 31 ASTRAZENECA FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 32 ASTRAZENECA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 33 ASTRAZENECA SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 34 AMGEN FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 35 AMGEN FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 36 AMGEN SWOT ANALYSIS AND STRATEGIC CONCLUSIONS

List of Tables

TABLE 1 CLINICAL TRIALS FOR ANTI-INFLAMMATORY DRUGS
TABLE 2 PATENT EXPIRY OF MAJOR BRANDS
TABLE 3 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 4 ASIA-PACIFIC ARTHRITIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 5 ASIA-PACIFIC RESPIRATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 6 ASIA-PACIFIC MULTIPLE SCLEROSIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 7 ASIA-PACIFIC PSORIASIS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 8 ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 9 ASIA-PACIFIC OTHER INFLAMMATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 10 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 11 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 12 ASIA-PACIFIC ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 13 ASIA-PACIFIC NSAIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 14 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 16 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014 2020 ($MILLION)
TABLE 17 JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 18 CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 19 INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 20 AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 21 SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 22 INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 23 REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 24 PFIZER INC SNAPSHOT
TABLE 25 ABBVIE INC. SNAPSHOT
TABLE 26 JOHNSON & JOHNSON SNAPSHOT
TABLE 27 GLAXOSMITHKLINE SNAPSHOT
TABLE 28 MERCK & CO SNAPSHOT
TABLE 29 NOVARTIS AG SNAPSHOT
TABLE 30 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 31 ELI LILLY SNAPSHOT
TABLE 32 ASTRAZENECA SNAPSHOT
TABLE 33 AMGEN INC SNAPSHOT

...
Publisher Name : Allied Market Research

SIMILAR MARKET STUDIES

Please Select Format
Single User :- US $ 2850
Five User:- US $ 3525
Enterprise User:- US $ 4920

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top